File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients

TitleA four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients
Authors
Issue Date2018
PublisherSpringer Nature [academic journals on nature.com]: Hybrid Journals. The Journal's web site is located at http://www.nature.com/leu
Citation
Leukemia, 2018, v. 32 n. 2, p. 263-272 How to Cite?
AbstractPrognostic gene expression signatures have been proposed as clinical tools to clarify therapeutic options in acute myeloid leukemia (AML). However, these signatures rely on measuring large numbers of genes and often perform poorly when applied to independent cohorts or those with older patients. Long intergenic non-coding RNAs (lincRNAs) are emerging as important regulators of cell identity and oncogenesis, but knowledge of their utility as prognostic markers in AML is limited. Here we analyze transcriptomic data from multiple cohorts of clinically annotated AML patients and report that (i) microarrays designed for coding gene expression can be repurposed to yield robust lincRNA expression data, (ii) some lincRNA genes are located in close proximity to hematopoietic coding genes and show strong expression correlations in AML, (iii) lincRNA gene expression patterns distinguish cytogenetic and molecular subtypes of AML, (iv) lincRNA signatures composed of three or four genes are independent predictors of clinical outcome and further dichotomize survival in European Leukemia Net (ELN) risk groups and (v) an analytical tool based on logistic regression analysis of quantitative PCR measurement of four lincRNA genes (LINC4) can be used to determine risk in AML.
Persistent Identifierhttp://hdl.handle.net/10722/267375
ISSN
2017 Impact Factor: 10.023
2015 SCImago Journal Rankings: 5.142
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorBeck, D-
dc.contributor.authorThoms, JAI-
dc.contributor.authorPalu, C-
dc.contributor.authorHerold, T-
dc.contributor.authorShah, A-
dc.contributor.authorOlivier, J-
dc.contributor.authorBoelen, L-
dc.contributor.authorHuang, Y-
dc.contributor.authorChacon, D-
dc.contributor.authorBrown, A-
dc.contributor.authorBabic, M-
dc.contributor.authorHahn, C-
dc.contributor.authorPerugini, M-
dc.contributor.authorZhou, X-
dc.contributor.authorHuntly, BJ-
dc.contributor.authorSchwarzer, A-
dc.contributor.authorKlusmann, JH-
dc.contributor.authorBerdel, WE-
dc.contributor.authorWormann, B-
dc.contributor.authorBuchner, T-
dc.contributor.authorHiddemann, W-
dc.contributor.authorBohlander, SK-
dc.contributor.authorTo, LB-
dc.contributor.authorScott, HS-
dc.contributor.authorLewis, ID-
dc.contributor.authorD'Andrea, RJ-
dc.contributor.authorWong, WHJ-
dc.contributor.authorPimanda, JE-
dc.date.accessioned2019-02-18T09:00:44Z-
dc.date.available2019-02-18T09:00:44Z-
dc.date.issued2018-
dc.identifier.citationLeukemia, 2018, v. 32 n. 2, p. 263-272-
dc.identifier.issn0887-6924-
dc.identifier.urihttp://hdl.handle.net/10722/267375-
dc.description.abstractPrognostic gene expression signatures have been proposed as clinical tools to clarify therapeutic options in acute myeloid leukemia (AML). However, these signatures rely on measuring large numbers of genes and often perform poorly when applied to independent cohorts or those with older patients. Long intergenic non-coding RNAs (lincRNAs) are emerging as important regulators of cell identity and oncogenesis, but knowledge of their utility as prognostic markers in AML is limited. Here we analyze transcriptomic data from multiple cohorts of clinically annotated AML patients and report that (i) microarrays designed for coding gene expression can be repurposed to yield robust lincRNA expression data, (ii) some lincRNA genes are located in close proximity to hematopoietic coding genes and show strong expression correlations in AML, (iii) lincRNA gene expression patterns distinguish cytogenetic and molecular subtypes of AML, (iv) lincRNA signatures composed of three or four genes are independent predictors of clinical outcome and further dichotomize survival in European Leukemia Net (ELN) risk groups and (v) an analytical tool based on logistic regression analysis of quantitative PCR measurement of four lincRNA genes (LINC4) can be used to determine risk in AML.-
dc.languageeng-
dc.publisherSpringer Nature [academic journals on nature.com]: Hybrid Journals. The Journal's web site is located at http://www.nature.com/leu-
dc.relation.ispartofLeukemia-
dc.titleA four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients-
dc.typeArticle-
dc.identifier.emailWong, WHJ: jwhwong@hku.hk-
dc.identifier.authorityWong, WHJ=rp02363-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/leu.2017.210-
dc.identifier.hkuros296867-
dc.identifier.volume32-
dc.identifier.issue2-
dc.identifier.spage263-
dc.identifier.epage272-
dc.identifier.isiWOS:000424517300003-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats